Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc. is positioned favorably in the biotech sector due to the promising interim biomarker results and lung function data associated with its lead product candidates, GRI-0621 and GRI-0803. The company's current valuation reflects an attractive opportunity, as it maintains a BUY rating while indicating significant upside potential based on net present value (NPV) analyses. Additionally, the observed positive impacts on fibrogenesis, fibrolysis, and safety metrics from recent data support the company's trajectory towards commercializing impactful therapies for serious autoimmune and inflammatory disorders.

Bears say

GRI Bio Inc reported a net loss of $3.4 million, or an earnings per share (EPS) of $(1.28), which significantly exceeded both personal estimates of $(1.11) and consensus expectations of $(0.93). Additionally, the company experienced another net loss of $3.9 million with an EPS of $(7.72), again falling short of projections that were $(4.08) and $(5.44) respectively, indicating consistently poorer financial performance than anticipated. Key risks impacting the company's financial outlook include balance sheet and liquidity challenges, potential failures in clinical trial outcomes, and the pressures of regulatory approvals, all of which contribute to a pessimistic view of GRI Bio's stock.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.